INTRODUCTION
Osteoclasts, responsible for bone resorption, are large multinucleated cells formed by fusion of hematopoietic precursor cells of the monocyte/macrophage family. Osteoclasts usually have between 10 and 20 nuclei per cell but may have as many as 100 (Roodman, 1996) . They are formed continuously throughout life under normal physiological conditions to maintain calcium homeostasis and to support normal bone remodeling. In response to hormones and mechanical stimuli, the mononuclear hematopoietic lineage cells fuse to form the differentiated osteoclast (Saltman, 2005) . During osteoclast differentiation, signature phenotypic markers are expressed including tartrate-resistant acid phosphatase (TRAP), the calcitonin receptor, matrix metalloproteinase 9 (MMP-9), and cathepsin K (Suda, 1999; Vaananen and Zhao, 2002; Boyle, 2003; Teitelbaum and Ross, 2003; Saltman, 2005) .
The discovery that receptor activator of NF-kB ligand (RANKL) is the major physiological mediator of osteoclast differentiation enabled investigators to generate pure populations of osteoclasts in vitro from the mononuclear phagocyte precursor (Lacey, 1998; Yasuda, 1998) . This major breakthrough led to a greater understanding of the mechanisms controlling osteoclast differentiation and activity under normal biological and pathological conditions (Boyle, 2003; Teitelbaum and Ross, 2003; Saltman, 2005) . A murine macrophage cell line, RAW264.7, can differentiate readily into osteoclast-like cells in the presence of RANKL (Hsu, 1999) . Known markers of osteoclasts are induced in the multinuclear TRAP-positive cells that form from the RAW264.7 cells, confirmation that these cells possess major characteristics of osteoclasts (Hotokezata, 2002) . RANK signaling pathways driven by RANKL, are controlled at several levels resulting in enhanced or reduced osteoclastogenesis. Activation of osteoclast surface receptors for IL-1, cFms proto-oncogene, tumor necrosis factor alpha (TNF-α), prostaglandin E 2 (PGE 2 ), and T-cell growth factor beta (TGF-β) potentiate osteoclastogenesis in vitro, and can stimulate bone resorption in vivo (Boyle, 2003) .
The Cannabis plant has been a source of medicinal preparations since the earliest written records on pharmacobotany. A major obstacle to broad acceptance of cannabinoids as therapeutic agents is their potent psychoactive effects. A class of cannabinoids, the carboxyl tetrahydrocannabinols, which are metabolites of tetrahydrocannabinol (THC), shows promise as therapeutic agents that are free of cannabimimetic central nervous system activity (Burstein, 1972) . These compounds, called cannabinoid acids, include all the carboxylic acid metabolites of the cannabinoids and their synthetic analogs. One analog, 1'1'-dimethylheptyl-THC-11-oic acid, termed ajulemic acid (AjA), is a potent antiinflammatory and analgesic agent in several animal models (Dajani, 1999) . In addition, AjA is not psychoactive in mice. In fact, AjA suppresses THC-induced catalepsy in mice (Burstein, 1999) . AjA, given to rats orally, reduces significantly the severity of adjuvant-induced polyarthritis in rats. Histomorphological evaluation of the joints suggested that synovial inflammation occurred in treated animals, but that it did not progress to cartilage degradation, bone erosion, and distortion of joint architecture, as was observed in rats given placebo . Results of experiments presented in this paper indicate that AjA suppresses osteoclastogenesis in vitro.
Many adult skeletal diseases are due to excess osteoclastic activity, leading to an imbalance in bone remodeling which favors resorption (Rodan, 2000) . These include osteoporosis, periodontal disease, rheumatoid arthritis, multiple myeloma, and metastatic cancers (Boyle, 2003) . For individuals with osteoporosis, bone fractures can represent life-threatening events, and today in excess of 70 million people worldwide are at risk (Boyle, 2003) . In an initial examination of the effects of AjA on osteoclasts, we observed that addition to mononuclear precursors suppressed osteoclastogenesis and also reduced cell number. In an investigation of the observed reduced cell number, we discovered that AjA induced apoptosis of osteoclasts.
Apoptosis is recognized as a mode of cell death in which cells are deleted in the midst of living tissue (Kerr, 1972) . Apoptotic cells express characteristic features such as cell shrinkage, nuclear condensation, loss of membrane microvilli, and surface blebbing (Wyllie, 1984) . Fragments of apoptotic cells are digested by resident phagocytes without influx of inflammatory cells (Polunovsky, 1993) . Thus, in contrast to cell death by necrosis, apoptosis is regulated and has been termed "programmed cell death" (Cohen, 1993) . It is possible that the effects of AjA on osteoclastogenesis and on osteoclast cell number will have a protective effect in diseases such as osteoporosis and rheumatoid arthritis characterized by excess osteoclast activity.
MATERIALS AND METHODS
AjA was obtained from Organix (Woburn, MA). Its purity was monitored on highpressure liquid chromatography by comparison with material synthesized previously (Burstein, 1992) . The sample was 97% chemically pure, and was >99% chirally pure in the enatiomer.
Establishment of Osteoclast Cultures. RAW264.7 cells were thawed and transferred to100mm plates (Corning, Corning, NY), and cultured 6-7 days in DMEM medium supplemented with 10% FBS, 2mM L-glutamine and 1% (v/v) penicillin-streptomycin (R&D Systems, Minneapolis, MN). To induce RAW264.7 cells to differentiate into osteoclasts, bacterially-produced recombinant RANKL (5ng/ml) was added. RAW264.7 cells were plated at the density of 2X10 5 /plate when no RANKL was added, and 4X10 5 /plate when RANKL was added.
Osteoclast staining. Osteoclast formation was monitored cytochemically by staining for tartrate-resistant acid phosphatase (TRAP). TRAP is regarded as an osteoclast marker and is mostly characterized by its biochemical property, i.e., through its acid phosphatase function, which cannot block tartrate (Filgueira, 2004) . A histochemical method, commercially available as a kit by Sigma Diagnostics (St Louis, MO), is widely used and has proved to be the standard method for specific detection of osteoclasts. After TRAP staining, the numbers of osteoclasts (with ≥3 nuclei) were quantified by counting in 3 different fields. Detection System. (Saltman, 2005) The relative level of each mRNA was determined using the comparative CT method for relative quantitation using GAPDH as an endogenous reference (Livak and Schmittgen, 2001 ).
RNA
Cell Growth. RAW264.7 cells (1X10 6 ) were plated and allowed to settle for 2 days. AjA was added to the media on the third day. Cells were scraped, pelleted, and resuspended in 1mL
of PBS on each of the three days of AjA treatment. Cells were then counted in a standard hemocytometer.
Annexin V Staining for Apoptosis. Phosphatidyl serine (PS) is located in the inner
leaflet of the plasma membrane. Early in the apoptotic process, reorganization of the phospholipid bilayer leads to the exposure of PS on the cell surface. The anticoagulant annexin-V binds with high affinity to PS in the presence of calcium (van Engeland, 1997).
RAW264.7 cells ( 1X10 6 ) were plated and allowed to settle for 2 days. RANKL and AjA were added to the fresh media on the third day. Media was replaced and fresh RANKL and AjA were added on the fifth day. Cells were processed on each of the three days of RANKL and AjA treatment. Cells were scraped and the cell number was adjusted to 1X10 6 cells/ml.
Cells were prepared using the RAPID Annexin V Binding Protocol from the Annexin V FITC Apoptosis Detection Kit (Calbiochem, La Jolla, CA). Annexin V binding was measured by flow cytometry.
Caspase-8 and Caspase-3 Activities. Caspase-8 and caspase-3 activities were quantified using a colorimetric assay in which caspases recognize the amino acid sequence IETD (Chemicon International, Temecula, CA). RAW264.7 cells were prepared as described in 
RESULTS

Suppression of Osteoclastogenesis by Ajulemic Acid.
AjA reduces release of the inflammatory cytokine interleukin-1β (IL-1β) from peripheral blood and synovial fluid monocytes, and prevents bone degradation in a rat model of inflammatory arthritis (Zurier, 2003; . Because preosteoclasts are in the monocyte lineage, we initiated these studies to understand the direct effects of AjA on both osteoclast differentiation and activity. Therefore, our experimental approaches examined the effects of AjA on the RANKL dependent induction of mononuclear cells to fuse and differentiate into osteoclasts, and the effects of AjA on the activity of mature osteoclasts. We first established conditions for introducing AjA and RANKL into the RAW264.7 cell cultures. AjA added simultaneously with RANKL to induce RAW264.7 cells results in suppression by AjA of osteoclastogenesis (osteoclasts are not present at the initial time of treatment) (Fig 1) . Addition of RANKL for 3 days before addition of AjA changes the condition to one in which AjA affects osteoclasts that are already formed. Addition of AjA first, washing it out, and then treating RAW264.7 cells with RANKL indicates whether the cells retain a "memory" of their exposure to
AjA.
First, we examined the simultaneous addition of AjA and RANKL to mononuclear RAW264.7 cells and monitored osteoclastogenesis by tartrate-resistant acid phosphatase (TRAP) staining, osteoclast number, and expression of osteoclast marker gene mRNA levels. In a series of three experiments, it was found that when RAW264.7 cells were treated with RANKL and AjA together (day 0) for three days, osteoclastogenesis was consistently supressed in a dose dependent manner (Fig 1A) . Low doses of AjA (0, 0.01, 0.1, and 1 μM) did not impair osteoclastogenesis substantially, whereas doses of AjA equal to or higher than 15 μM suppressed osteoclastogenesis significantly (Fig 1B) . Osteoclast counts were performed by light microscopy in three different fields. We observed that osteoclasts (>3 nuclei) formed after exposure of cells to 15μM AjA all were smaller in size, but had fewer nuclei per cell compared to cells treated with 1μM AjA. These observations suggest that AjA impaired the ability of monocytes to fuse.
In all three experiments osteoclastogenesis, as measured by TRAP staining and by direct counting, was reduced significantly by 20 μM or more of AjA.
To further evaluate the effect of AjA on osteoclastogenesis, real time RT-PCR was used to assess relative mRNA levels of the osteoclast markers cathepsin K, an early marker, and TRAP, a marker of fully mature osteoclasts. We found that 30 μM AjA, but not the 15μM dose, reduced relative mRNA levels of RAW264.7 cells treated with AjA and RANKL simultaneously for three days (Fig 2) . In a series of 2 experiments, 30 μM AjA decreased TRAP mRNA 72.2%+5.1%, p=0.002 (mean+s.d., p vs control) and decreased cathepsin K mRNA 43.2%+49%, p=0.34 (mean+s.d., p vs control). Unexpectedly, the 15 μM dose resulted in a 3 fold increase in cathepsin K ( Fig 2B) and a greater than 2 fold increase in TRAP ( Effect of ajulemic acid on RAW264.7 cell growth.
In an effort to determine whether AjA suppression of osteoclastogenesis was due to an effect on the mononuclear cells or on the differentiated osteoclasts, we first investigated the effect of AjA on RAW264.7 cell growth. RAW264.7 cells were plated at 50% below normal density, allowed to adhere for 48 hours, and AjA added at 2 doses. The cells exhibited log phase growth from day 1 to day 3 (Fig 3A) . AjA reduced cell numbers in a dose-dependent manner on day 3. Thus, cell growth was reduced 21.9% at 15 μM and 46.1%, p=0.006 vs untreated controls at 30 μM respectively (Fig 3A) . We next treated RAW264.7 cells with AjA for only 24 hr, before harvest on day 3 (Fig 3B) . Cell numbers were not affected significantly (Fig 3B) . Thus, AjA does not appear toxic to mononuclear cells. Our results indicate that growth of RAW264.7 cells is diminished by AjA before confluency (day 2; Fig 3A) , thereby reducing the number of precursors available for osteoclast formation. These results are consistent with TRAP staining experiments described above in which fewer mononuclear cells and osteoclasts are present in AjA treated RAW264.7 cells in differentiating cultures (see Fig 1) .
Apoptosis caused by Ajulemic Acid.
The results presented in Figure 3 are from experiments with mononuclear RAW264.7 cells. To determine whether AjA acts on the osteoclasts after RANKL induced RAW264.7 differentiation, we tested the effects of AjA under two conditions. First, we formed osteoclasts with RANKL before addition of AjA. RAW264.7 cells were treated with RANKL for 3 days, then with 30 μM AjA during the final 24 hours of exposure to RANKL when osteoclasts were present (Fig 4) . TRAP staining was used to quantify the number of osteoclasts present on day 3.
AjA (15-30 μM) prevented further osteoclastogenesis (Fig 4A) and reduced the number of osteoclasts significantly (Fig 4B) . This result suggests that AjA induced apoptosis of differentiated osteoclasts.
To further address the possibility that AjA promoted apoptosis of both mononuclear cells and osteoclasts propidium iodide labeled cells and annexin V staining was assessed by FLOW cytometry (Fig 5) . In normal viable cells, phosphatidylserine (PS) is located on the cytoplasmic surface of the cell membrane. Upon induction of apoptosis, rapid alterations in the organization of phospholipids occurs in most cell types, leading to exposure of PS on the cell surface.
Detection in vitro of externalized PS can be achieved through interaction with the anticoagulant annexin V. In the presence of calcium, rapid high affinity binding of annexin V to PS occurs. PS translocation to the cell surface precedes nuclear breakdown, DNA fragmentation, and the appearance of most apoptosis-associated molecules, making annexin V binding a marker of early-stage apoptosis. (van Engeland, 1997) . For these studies RAW264.7 cells were treated or not with RANKL and with or without AjA on day 0 for 3 days. Both early (Fig 5A) and late ( Fig   5B) stage apoptotic cells were increased each day. In the absence of AjA, RAW264.7 cells stimulated with RANKL (thus forming osteoclasts) exhibited an initial increase in apoptosis,
indicating that apoptosis was induced in developing osteoclasts. Also, there was an increase in apoptosis at 24 hours in cultures treated with AjA and RANKL, which indicates an increase in apoptosis of RAW264.7 cells.
During apoptosis, the cysteine proteases (caspases) are activated (Nagata, 1997).
Addition of AjA to formed osteoclasts for 24 hours increased caspase 3 and caspase 8 activities, further indicating induction of osteoclast apoptosis by AjA (Figure 6 ).
Washout studies.
To determine whether the continuous presence of AjA in the RANKL stimulated RAW264.7 cell cultures is required for the suppressive activity, washout studies were done in which RAW264.7 cells were exposed to AjA for 2 or 24 hours, then washed extensively, and incubated with RANKL for 3 days. The results (Fig 7) showed that osteoclast formation was reduced even when AjA had been washed out of the system. Inclusions were noted in some osteoclasts, again suggesting induction of apoptosis by AjA. Indeed, AjA increased caspase 8 activity (Fig 8) . However, in washout studies with pure cultures of RAW264.7 cells, AjA did not induce inclusions or caspase 8 activity (not shown).
DISCUSSION
In this paper, we demonstrate that the synthetic nonpsychoactive cannabinoid ajulemic acid suppresses osteoclastogenesis in vitro in a concentration dependent manner. We observed (direct cell counts, histochemical staining, mRNA levels for osteoclast markers) that addition of AjA to RANKL stimulated precursor cells (RAW264.5 mouse macrophages) reduces osteoclast formation. These observations did not distinguish between an effect of AjA on the RAW264.7 cells or on the mature osteoclasts. Therefore, under the influence of RANKL, RAW264.7 cells were allowed to differentiate into osteoclasts before exposure to AjA. Results of these experiments indicate that AjA acts directly on osteoclasts to reduce their number. Inclusions observed in these cells suggested that the osteoclasts were undergoing programmed cell death.
Assessment of apoptosis by FLOW cytometry (annexin V and propidium iodide) and measurement of caspases 3 and 8 confirmed that process. Although AjA is not toxic to RAW264.7 cells, it does induce apoptosis in these osteoclast precursors when they are exposed to RANKL. Thus, apoptosis of developing osteoclasts and of fully formed osteoclasts explains, at least in part, the capacity of AjA to suppress osteoclastogenesis in vitro. Moreover, washout studies indicate that continuous presence of AjA in not necessary for the anti-osteoclastogenesis effect.
The precise manner by which AjA signals the precursor cells or the osteoclasts is not clear. AjA binds only weakly to CB2, the predominant cannabinoid receptor on macrophages (Rhee, 1997) . Although we have shown (Liu, 2003) that AjA binds to and activates the nuclear receptor and transcription factor PPARγ, we have also observed (Johnson, 2007) that AjA suppresses production of several matrix metalloproteinases in a PPARγ independent manner.
Although osteoporosis is likely caused by complex interactions among local and systemic regulators of bone cell function, it is clear that excessive bone resorption resulting in loss of bone mass and strength is central to the process (Raisz, 2005) . Recent experimental evidence indicates that activation of osteoclasts is also central to the pathogenesis of bone resorption in joints of patients with RA (Gravallese, 2002) . It is clear that cytokines such as interleukin-1 (IL-1) and IL-6 facilitate not only inflammation and immune responses, but bone resorption as well. Both IL-1 and IL-6 stimulate osteoclastogenesis (Wei, 2005; Kotakeetal, 1996) . It is of interest then that AjA suppresses production of IL-1β by human peripheral blood and synovial fluid monocytes (Zurier, 2002) , and of IL-6 by human monocyte derived macrophages (Parker, unpublished).
Endocannibinoids are endogenous compounds capable of binding to and functionally activating the two known cannabinoid receptors, CB1 and CB2 (Dimarzo, 2002) . Recent observations suggest that endocannibinoids also interact with non-CB1, non-CB2 G protein coupled receptors and several ion channels (Dimarzo, 2002) . The endocannabinoid system regulates bone mass in mice (Ofek, 2006; Karsek, 2004; Idris, 2005) . CB2 deficient mice exhibit markedly accelerated age-related trabecular bone loss reminiscent of human osteoporosis (Ofek, 2006) . In addition, a CB2-specific agonist enhances endocortical osteoblast number and activity, and impairs trabecular osteoclastogenesis (Ofek, 2006) . In this context, our findings presented here that AjA suppresses osteoclastogenesis in vitro, and our observation that administration of
AjA in vivo prevents bone erosion in adjuvant induced arthritis in rats , encourage its further use in animal models, and suggest that AjA may prove to be safe, effective treatment for osteoporosis and rheumatoid arthritis, conditions characterized by excessive osteoclast activity.
Now that psychoactivity can be separated from the medicinal properties of Cannabis products, and pure constituents are available or can be isolated from the plant, it is important to understand which constituents or combination of constituents of marijuana are responsible for the biological and pharmacological activities of the whole plant. Such knowledge, and synthesis of analogs of plant constituents, might lead to development of new, more benign treatment for diseases associated with inflammation and bone loss. AjA suppresses osteoclastogenesis. Quantitive real time PCR of osteoclast phenotypic gene markers. Cells were cultured for 6 days in the absence (purple bar) or presence (magenta bar) of RANKL as described in "Materials and Methods." Total RNA was extracted, reverse transcribed, and subjected to real time PCR analysis using primers for known osteoclast markers. Values are normalized for GAPDH expression and expressed in arbitrary units. AjA suppresses osteoclastogenesis. Quantitive real time PCR of osteoclast phenotypic gene markers. Cells were cultured for 6 days in the absence (purple bar) or presence (magenta bar) of RANKL as described in "Materials and Methods." Total RNA was extracted, reverse transcribed, and subjected to real time PCR analysis using primers for known osteoclast markers. Values are normalized for GAPDH expression and expressed in arbitrary units. 
FIGURES AND LEGENDS
Effect of
